Theraclion Aligns Its Investor Structure and Financial Leadership with Its Long-Term Commercial Ambitions

A major German institution invests in Theraclion
David Auregan joins as new Chief Financial Officer

MALAKOFF, France--()--Regulatory News:

THERACLION (Paris:ALTHE) (Alternext, FR0010120402 – ALTHE), a company specialized in leading-edge medical equipment for echotherapy, is pleased to announce the investment of a major German bank into its capital on the one hand and the nomination of a new Chief Financial Officer, David Auregan, on the other.

A major German Institution acquires stake in Theraclion
A major German bank invested into Theraclion capital by acquisition of shares from its historical shareholder, Truffle Capital. Theraclion’s non-invasive treatment procedures are getting reimbursed by more public “Krankenkassen” (insurance companies) and have been recently introduced to several additional commercial reference sites in Germany. This increasing success in Germany led the financial institution to support Theraclion’s development and growth.

New addition to the executive management team
Theraclion also announced that David Auregan joins the company as Chief Financial Officer and is responsible for leading financial operations and activities as well as investor relations.
David Auregan served from 2010 as Chief Financial Officer for EFESO Consulting (Alternext, ALEFE) where he helped to multiply the company’s value by 3 in 5 years. Previously, he worked as Financial Planning & Analysis Manager for Carrier and as Financial Analyst and Cash Flow Project Manager for GE Healthcare. He started his career with Arthur Andersen. David is a graduate of EDHEC and holds an MBA from Newcastle University. He is a certified Lean Six Sigma Black Belt.

David succeeds Sarah Ankri. “I want to thank Sarah for a terrific contribution and I wish her the very best in new endeavours.” says David Caumartin, CEO Theraclion.

He adds: “These two additions are key assets to strengthen Theraclion’s future: a world-class bank joins our capital for a long-term partnership and an experienced financial leader joins our core team to help drive our company beyond current territories and indications, increasing value for patients, customers and shareholders.”

About Theraclion
Theraclion is a French company specializing in high-tech medical equipment using therapeutic ultrasound. Drawing on leading-edge technologies, Theraclion has designed and manufactured an innovative solution for echotherapy, the Echopulse®, allowing non-invasive tumor treatment through ultrasound-guided high-intensity focused ultrasound.
Theraclion is ISO 13485 certified and has received the CE mark for non-invasive ablation of breast fibroadenomas and thyroid nodules. Based in Malakoff, near Paris, France Theraclion has brought together a team of 30 people, 53 percent of whom are dedicated to R&D and clinical trials. For more information, please visit Theraclion’s website: www.theraclion.com.

Theraclion is listed on Alternext Paris
PEA-PME Eligible
Mnemonic: ALTHE - ISIN Code: FR0010120402

Contacts

Theraclion
David Caumartin, +33 (0)1 55 48 90 70
CEO
david.caumartin@theraclion.com
or
NewCap
Financial Communications & Investors relations
Emmanuel Huynh / Valentine Brouchot, +33 (0)1 44 71 94 94
theraclion@newcap.fr
or
Kalima
Press Relations
Estelle Reine-Adélaïde/ Florence Calba, + 33 (0)1 44 90 82 54
era@kalima-rp.fr

Contacts

Theraclion
David Caumartin, +33 (0)1 55 48 90 70
CEO
david.caumartin@theraclion.com
or
NewCap
Financial Communications & Investors relations
Emmanuel Huynh / Valentine Brouchot, +33 (0)1 44 71 94 94
theraclion@newcap.fr
or
Kalima
Press Relations
Estelle Reine-Adélaïde/ Florence Calba, + 33 (0)1 44 90 82 54
era@kalima-rp.fr